Adicet Bio (ACET) Projected to Release Earnings on Thursday

Adicet Bio (NASDAQ:ACET) will likely be releasing its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect Adicet Bio to announce earnings of ($1.6920) per share for the quarter. Individuals can check the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Friday, August 14, 2026 at 4:00 PM ET.

Adicet Bio (NASDAQ:ACET) last released its earnings results on Wednesday, May 13th. The company reported ($1.88) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.93) by $1.05. On average, analysts expect Adicet Bio to post $-9 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Adicet Bio Stock Performance

Shares of ACET stock opened at $9.21 on Wednesday. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.66 and a quick ratio of 7.65. The business has a fifty day moving average of $8.36 and a 200 day moving average of $7.81. The firm has a market capitalization of $86.11 million, a price-to-earnings ratio of -0.62 and a beta of 1.60. Adicet Bio has a 1 year low of $6.01 and a 1 year high of $17.44.

Hedge Funds Weigh In On Adicet Bio

Institutional investors have recently made changes to their positions in the company. Susquehanna International Group LLP purchased a new stake in Adicet Bio during the third quarter worth $33,000. Squarepoint Ops LLC purchased a new position in Adicet Bio in the third quarter valued at $38,000. Luminus Management LLC purchased a new position in Adicet Bio in the fourth quarter valued at $501,000. Burkehill Global Management LP acquired a new position in shares of Adicet Bio in the fourth quarter worth about $526,000. Finally, Virtu Financial LLC acquired a new position in shares of Adicet Bio in the third quarter worth about $65,000. 83.89% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on ACET. Jefferies Financial Group began coverage on Adicet Bio in a report on Tuesday, May 5th. They set a “buy” rating and a $19.00 target price for the company. Weiss Ratings upgraded shares of Adicet Bio from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, May 26th. Finally, Wall Street Zen upgraded shares of Adicet Bio from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $48.80.

About Adicet Bio

Adicet Bio, Inc (NASDAQ: ACET) is a clinical‐stage biotechnology company specializing in the development of off‐the‐shelf, allogeneic gamma delta (γδ) T cell therapies for oncology and autoimmune disorders. The company’s proprietary platform enables the genetic engineering of γδ T cells with chimeric antigen receptors (CARs) and other molecular modifications to enhance tumor targeting, expansion, and persistence. By leveraging the innate tumor-recognition properties of γδ T cells, Adicet seeks to overcome the manufacturing and safety challenges associated with autologous cell therapies.

Adicet’s lead product candidate, ADI-001, is a CAR‐engineered allogeneic γδ T cell therapy directed against CD20 for the treatment of relapsed or refractory B-cell malignancies.